Diasorin SpA (CHIX:DIAM) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DIAM Diasorin SpA CHIX:DIAM
78 GF Score
Price €69.54
GF Value €90.24
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Diasorin SpA SpecialCharges?

Special Charges only applies to banks.

CHIX:DIAM
78GF Score
Diasorin SpA CHIX:DIAM
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Diasorin SpA (CHIX:DIAM) Overvalued in 2026?

Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued. The current stock price of €69.54 is trading 22.9% below its estimated GF Value™ of €90.24. GuruFocus considers Diasorin SpA to be Modestly Undervalued.

Key valuation signals for CHIX:DIAM:

  • SpecialCharges:
  • GF Value™: €90.24 vs. price of €69.54 (22.9% below fair value)
  • GF Score™: 78/100 with 6 warning signs

No single metric tells the full story. See the CHIX:DIAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diasorin SpA Business Description

Address Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
78GF Score

Get the complete analysis for CHIX:DIAM

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€69.54
Price
€90.24
GF Value